PRVCF - PreveCeutical Medical Inc.
| Previous Close | 0.0218 |
| Open | 0.0219 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0218 - 0.0218 |
| 52 Week Range | 0.0109 - 0.0299 |
| Volume | |
| Avg. Volume | 38,249 |
| Market Cap | 11.67M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfilePreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent Application No. PCT/AU2021/051383, Sol-Gel Cannabinoid Formulation and Antiviral Use) and is taking the International patent application forward in the US and Canada, with plans to progress in Europe and
- Newsfile
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intelligence (AI) tool that will be capable of learning R&D, clinical trials, and other clinical information.PreveCeutical plans to use this tool in the development and process of all our clinical programs. This ...
NewsfilePreveCeutical Medical Announces Live Interactive Q&A Video Conference
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that Stephen Van Deventer will be participating in a live interactive video conference Q&A forum on April 25, 2023.All participants are encouraged to pre-register to ensure access to the live virtual event and to submit any questions they may have prior to enable the producers to reduce duplications of queries
NewsfilePreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Synthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Side-effects Such as Tolerance, Addiction, Sedation, and Euphoria/Dysphoria,KOP Peptides Showed Significant Opioid-like Antinociception Comparable to Morphine and U50844HPreveCeutical's Pain Management Peptides Program Published in the Swiss Medical Journal.Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "P
NewsfilePreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following.Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those a
NewsfilePreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical is furthering the progress of its Sol-Gel Cannabinoid Therapies patent family based on International Patent Application PCT/IB2021/022211 (Thermoresponsive Sol-Gels containing cannabinoids), and is taking the International patent application forward in the US, Europe, Canada and Australia.The
NewsfileAppointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the appointment of Mr. Evan Ballantyne to the Company's board of directors (the "Board") effective February 17, 2023.Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief Financial Officer in the healthcare industry. He was most recently the CFO
NewsfilePreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in the p
NewsfilePreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has licensed it exclusively to PreveCeutical. The Australian p
NewsfilePreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform te
NewsfilePreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the International patent application forward in the US, Europe, Canada and A
NewsfilePreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis (th
NewsfilePreveCeutical Signs Intercompany Sol-Gel License Agreement
Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids ("Sol-Gel License").PAPL has an exclusive license agreement with UniQue
ACCESSWIREThe Power Play by The Market Herald Releases New Interviews with Eloro Resources, Prospera, Datametrex, Gamelancer Media, Infinity Stone Ventures and PreveCeutical Medical Discussing Their Latest News
The Power Play by The Market Herald has announced the release of new interviews with Eloro Resources, Prospera, Datametrex, Gamelancer Media, Infinity Stone Ventures and PreveCeutical Medical discussing their latest news.
NewsfilePreveCeutical Files Application for D-amino Acid Peptides
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a PCT (Patent Cooperation Treaty) application number PCT/IB2022/06117 on November 18, 2022, entitled "Peptides and Uses Thereof", with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer.This patent application is made to
- Newsfile
PreveCeutical Announces Conversion of Debt
Vancouver, British Columbia--(Newsfile Corp. - November 11, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into an assignment agreement with a certain arm's length assignee (the "Assignee").Per the assignment agreement, the Assignee acquired all of Stephen Van Deventer and Kimberly Van Deventer's rights, title, interests and obligations in and under a convertible credit facility agreement dated effective
NewsfileAppointment of Kathleen Rotika to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the appointment of Ms. Kathleen Rotika ("Kathy") to the Company's board of directors (the "Board").Kathy is a CPA and Principal of Somerset CPA's P.C. She is a finance, operations, and strategy-focused executive with extensive experience with large medical groups. Her experience includes financial performance improvemen
- Newsfile
PreveCeutical Announces Resignation of Board of Director Member
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Sachin Nanavati as a member of the Company's board of director (the "Board") for personal reasons effective September 16, 2022.Stephen Van Deventer, PreveCeutical's Chief Executive Officer, commented, "We thank Mr. Nanavati for considering to be on the Company's Board and wish him all the best."A
NewsfileAppointment of Sachin Nanavati to PreveCeutical's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022.Sachin is currently the Head of Industry, Healthcare with Google, Inc. He has vast knowledge and experience with healthcare and technology. Sachin was a founding member of Meta (Facebook)'s Health Team, w
- Newsfile
PreveCeutical Enters into Credit Facility Agreement
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a $3 million credit facility agreement with the Company's Chief Executive Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders").Effective July 18, 2022, the Company entered into a convertible credit facility agre